Wealth Enhancement Slashes Alnylam Pharmaceuticals, Inc. (ALNY) Stake by 64.5%

Core Insights - Alnylam Pharmaceuticals, Inc. is recognized as a promising biotech stock, with hedge funds showing interest despite a recent reduction in holdings by Wealth Enhancement Advisory Services LLC [1][2][3] - The company is expected to achieve over $1 billion in quarterly revenue by year-end and more than $1 billion in adjusted earnings in the upcoming year, highlighting its strong commercial execution and clinical productivity [2][3] - Alnylam's stock has outperformed the market by nearly 50% over the past year, driven by the successful launch of Amvuttra in TTR-CM, which has significantly boosted revenues [3][4] Company Overview - Alnylam Pharmaceuticals, Inc. is based in Massachusetts and specializes in therapeutics based on ribonucleic acid interference (RNAi), aiming to establish itself as a leading biopharmaceutical company [4]